Background
Histological subtype information in breast cancer is clinically relevant for treatment purposes but insufficient to describe all tumor heterogeneity [
1]. The basal-like molecular subtype, which typically expresses cytokeratins 5/6 and EGFR, frequently overlaps with the histological subtype of triple-negative (TN) breast cancer [
2,
3]. TN breast cancer is described by the absence of ERα/PR and HER2 expression and poor overall prognosis [
4,
5]. Because of the lack of available targeted therapies for this subtype, the clinical impact of target discovery for patients with TN breast cancer is potentially significant.
Hereditary germline
BRCA1 mutations are found in around 12% of all TN breast cancers [
6‐
8]. BRCA1 plays a critical role in error-free DNA double-strand break repair via homologous recombination, and deficiency can result in genomic instability [
9,
10]. Differential gene expression patterns in
BRCA1 mutant tumors versus nonmutant tumors have been identified previously [
11‐
14]. Because of the relative rarity of
BRCA1 mutation in the general breast cancer population [
15], however, these studies are often underpowered, making clinical impact for mutation carriers limited. Furthermore, the capacity of these signatures to predict response to targeted treatments such as PARP inhibitors has not been thoroughly explored in the randomized clinical trial setting.
BRCA1-mutated/promoter-methylated TN tumors with a specific pattern of copy number alterations are termed
BRCA1-like [
16‐
20]. ‘
BRCAness’ describes tumors with molecular features of BRCA1-mutated tumors [
21,
22]. Interestingly, the whole group of
BRCA1-like tumors responds well to DNA double-strand break-inducing agents and intensifying chemotherapy regardless of their
BRCA1 mutation/promoter methylation status [
16,
23,
24]. These findings suggest that a relatively large portion of TN breast cancers may be susceptible to targeted therapies such as PARP inhibitors. The efforts of many groups have resulted in various classifiers for
BRCAness, typically based on mutation [
13,
14,
25] or homologous recombination repair deficiency (HRD) markers [
26] and using gene expression data as an input. Recent work has found that an assay designed to detect
BRCAness using HRD as a biomarker failed to predict for carboplatin response [
27], illustrating the challenges of generating a signature with the capacity to predict treatment effect [
28].
Molecular subgroups within the TN subtype have differential benefit from therapies [
29‐
31]. In addition, previous work in TN tumors has determined that differentially expressed genes between
BRCA1-like and non-
BRCA1-like tumors center around DNA repair [
29,
32,
33] and may lead to new information for clinical therapeutic decisions. A test based on gene expression levels may also lead to insight into the mechanisms which result in tumors with
BRCA1-like features. We developed a 77-gene signature to identify samples with a
BRCA1-like gene expression pattern we term
BRCA1ness with a sensitivity and specificity of 96.7% and 73.1%, respectively. We explored this signature’s ability to predict response to the PARP inhibitor veliparib in combination with carboplatin (V-C) in the I-SPY 2 TRIAL, a phase 2, multicenter, adaptively randomized trial designed to screen multiple experimental regimens in combination with standard neoadjuvant chemotherapy for breast cancer, where V-C graduated in the TN signature [
34‐
36]. Investigation of the
BRCA1ness signature was part of a further evaluation of additional biomarkers in this setting. In this study, we aimed to answer the clinical question in the I-SPY 2 external validation set of whether to treat with PARP inhibition based on the well-studied mechanism of HRD (identified by our biomarker
BRCA1ness).
Discussion
At around 15% of all breast cancers, the TN breast cancer subtype impacts a significant proportion of women [
7,
40]. TN breast cancer tends to be aggressive independent of other known prognostic factors [
5,
41]. Current guidelines indicate that standard therapy for TN breast cancer is chemotherapy [
2]. Unfortunately, these tumors typically metastasize early despite therapy [
5,
41]. This poor response to treatment may be due to the fact that the TN subtype itself is made of molecular subgroups. Conversely, molecular data from these subgroups may indicate a targeted therapy, which is likely to benefit patients.
Because of results in preclinical models,
BRCA1 mutation carriers of multiple tumor types have been enrolled in clinical trials with PARP inhibitors [
27,
32,
42‐
44]. Currently, there are no other predictive biomarkers for PARP inhibitors other than the germline BRCA1 mutation status, and the issue with that biomarker is that it only captures a small subgroup of all patients that may benefit from carboplatin/veliparib [
8]. Previous work has shown that genomic instability patterns are related to
BRCA1 mutation/methylation and that these patterns can be used to classify tumors are
BRCA1-like or non-BRCA1-like [
16‐
20,
24]. These
BRCA1-like tumors make up a larger group than
BRCA1 mutant or methylated alone, and importantly they respond well to DNA double-strand break-inducing chemotherapies [
17,
23,
24]. We have developed a gene expression signature that is capable of identifying
BRCA1-like samples with a high sensitivity/specificity rate (
BRCA1ness).
Pathway analysis reveals that the genes in this signature are associated closely with cell cycle and cancer networks. We also observed a significant association with serine and glycine biosynthesis pathways with the genes of the signature. This is of particular interest because it has been recently shown that aerobic glycolysis signaling can promote tumor growth in breast cancer cell lines that are TN [
45], indicating that the poor outcome for patients with a
BRCA1ness tumor may be partially explained in this manner. Serine biosynthesis has been identified to be essential to tumorigenesis in estrogen receptor-negative breast cancer cell lines [
46]. We identified serine biosynthesis to be related specifically to the genes found in the
BRCA1ness gene expression signature, suggesting that tumors having
BRCA1-like features may have particular vulnerabilities to drugs that interfere with serine biosynthesis. It would be interesting to test whether high expression of genes involved in serine and glycine biosynthesis can confer sensitivity to drugs which interfere with this biosynthesis in breast cancer cell lines. In addition, we found that the signature is capable of predicting response to the PARP inhibitor veliparib in combination with carboplatin compared with a control treatment regimen.
Conclusion
The sample size in the I-SPY 2 TRIAL is small, but our prespecified analysis suggests that the
BRCA1ness signature shows promise for predicting response to V-C combination therapy relative to control. We focused on the experimental arm of the study that contains DNA-damaging agents because the
BRCA1ness test is meant to identify patients that may derive substantial benefit from these agents. We observed a proportion of patients who were hormone receptor-positive that benefited from the V-C treatment. It is unlikely in a regular clinical setting that hormone receptor-positive patients would be tested for
BRCA1ness, but our data indicate that these patients could derive benefit from specific tailored treatments like PARP inhibitors and/or platinum agents. Concurrently reported results studying carboplatin in TN breast cancer have indicated it may be difficult to translate the pCR rate to longer benefit such as recurrence-free survival (RFS) [
47‐
50]. It should be noted that, for this trial, we used a surrogate endpoint (pCR) for RFS and longer follow-up is required to investigate the
BRCA1ness classifier in relation to long-term benefit. In the event that downsizing of the tumor is required to facilitate conversion from mastectomy to breast-conserving therapy, this classifier may already have value. If verified in a larger trial, this signature may contribute to the selection criteria of PARP inhibitor trials in the future.
Acknowledgements
The authors would like to acknowledge all members of the RATHER Consortium: the collaborative European Union-funded effort FP7 RATHER project (
Rational
Therapy for Breast Cancer) (protect number: 258967) (
www.ratherproject.com). They also thank all I-SPY 2 TRIAL investigators and participants. In addition, the authors would like to acknowledge the effort and support of the Netherlands Cancer Institute (NKI) Core Facility Molecular Pathology and Biobanking (CFMPB) for supplying NKI Biobank material and support. The authors are grateful to Dr Esther Lips for supplying important data for preliminary analyses.